Search

Displaying results 2721 - 2730 of 2955 in total
  1. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    [A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH.

  2. Drug

    Deracoxib

    go.drugbank.com/drugs/DB11395
    ExperimentalVet approved

    Deramaxx received FDA approval in August 2002 for "the control of post operative pain and inflammation associated with orthopedic surgery in dogs.

  3. Drug

    Flunixin

    go.drugbank.com/drugs/DB11518
    ExperimentalVet approved

    Flunixin is regulated in the United States by the Food and Drug Administration (FDA) and must be prescribed by a licensed veterinarian.

  4. Drug

    Rindopepimut

    go.drugbank.com/drugs/DB05374
    Investigational

    The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015.

  5. Drug

    Corifollitropin alfa

    go.drugbank.com/drugs/DB09066
    ApprovedInvestigational

    FDA for its New Drug Application for this drug. Corifollitropin alfa is marketed as Elonva in more than 75 countries [L2272].

  6. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L42245] In January 2023, the FDA granted accelerated approval to intravenous mosunetuzumab based on response rate.

  7. Drug

    Benidipine

    go.drugbank.com/drugs/DB09231
    Investigational

    [A31948] It was originated in Japan by Kyowa Hakko, it is submitted for FDA approval and it is currently available in some Asian countries like India and Japan.[L1385, L1386]

  8. Drug

    Benzoylecgonine

    go.drugbank.com/drugs/DB01515
    ExperimentalIllicit

    It is the main pharmaceutical ingredient in the investigational drug Esterom, a topical solution used for the relief of muscle pain that is not FDA approved or on the market in the United States.

  9. Drug

    Davesomeran

    go.drugbank.com/drugs/DB17091
    ApprovedInvestigational

    [L43882] In October 22nd 2022, the FDA approved the Moderna Bivalent Vaccine as a booster in patients 6 years or older, administered at least 2 months after completion of primary vaccination or receipt

  10. Drug

    Maftivimab

    go.drugbank.com/drugs/DB15899
    ApprovedInvestigational

    INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320]